Department of Laboratory Medicine, Mayo Foundation, Rochester, Minnesota, USA.
Arch Pathol Lab Med. 2012 Jan;136(1):11-3. doi: 10.5858/arpa.2011-0212-ED.
With our ever-increasing understanding of the molecular basis of disease, clinical laboratories are implementing a variety of molecular diagnostic tests to aid in the diagnosis of hereditary disorders, detection and monitoring of cancer, determination of prognosis and guidance for cancer therapy, and detection and monitoring of infectious diseases. Before introducing any new test into the clinical laboratory, the performance characteristics of the assay must be "verified," if it is a US Food and Drug Administration (FDA)-approved or FDA-cleared test, or "validated," if it is a laboratory-developed test. Although guidelines exist for how validation and verification studies may be addressed for molecular assays, the specific details of the approach used by individual laboratories is rarely published. Many laboratories, especially those introducing new types of molecular assays, would welcome additional guidance, especially in the form of specific examples, on the process of preparing a new molecular assay for clinical use.
随着我们对疾病分子基础的认识不断加深,临床实验室正在实施各种分子诊断测试,以帮助诊断遗传性疾病、检测和监测癌症、确定预后并为癌症治疗提供指导,以及检测和监测传染病。在将任何新测试引入临床实验室之前,必须对检测方法的性能特征进行“验证”(如果它是美国食品和药物管理局 (FDA) 批准或 FDA 许可的测试)或“确证”(如果它是实验室开发的测试)。尽管有关于如何针对分子检测进行验证和确认研究的指南,但很少有出版物介绍个别实验室使用的具体方法细节。许多实验室,尤其是那些引入新型分子检测的实验室,将非常欢迎额外的指导,特别是以具体示例的形式,介绍为临床使用准备新分子检测的过程。